|
 |
| home > ebr > spring 2004 > can the new generation of biomarkers escape the commodity trap? |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| Diagnostics are involved in 80 per cent of all medical decisions, yet account for only four per cent of health care expenditure. Limited patent protection, combined with past aggressive price competition among laboratories and manufacturers, have yielded an industry whose economics are far removed from those of the pharmaceuticals that the diagnostics indicate. Attend a diagnostics industry discussion on the adoption of a new test, and sooner or later someone will say, "of course it depends on how much it will cost", a response much less often heard when appraising an important new drug. So diagnostics typically cost from a few cents to a few dollars (or pounds, or euros, if you prefer); innovative pharmaceuticals from hundreds to many thousands (of dollars, pounds or euros) per course of treatment. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
New PFA SonicLine® ultrasonic flowmeters
Flow measurement with ultrasound fast, precise, free from contamination The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.
More info >> |
|
 |
